LadRx (OTCMKTS:CYTR) vs. Neumora Therapeutics (NASDAQ:NMRA) Critical Survey

Neumora Therapeutics (NASDAQ:NMRA) and LadRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Neumora Therapeutics and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-73.63%	-68.97%
LadRx	N/A	-67.61%	-45.39%

Insider & Institutional Ownership

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 0.1% of LadRx shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by insiders. Comparatively, 12.8% of LadRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Neumora Therapeutics has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Neumora Therapeutics and LadRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	0	1	5	0	2.83
LadRx	0	0	0	0	0.00

Neumora Therapeutics currently has a consensus price target of $23.40, suggesting a potential upside of 106.53%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Neumora Therapeutics is more favorable than LadRx.

Valuation & Earnings

This table compares Neumora Therapeutics and LadRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$235.93 million	($1.87)	-6.06
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

Neumora Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Summary

Neumora Therapeutics beats LadRx on 6 of the 11 factors compared between the two stocks.

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.